Skip to main content Skip to main navigation menu Skip to site footer
International Journal of Nutrology
Articles
DOI: 10.1055/s-0040-1701422
Submitted: 24-01-2022
Published: 25-01-2022

Nutrology and type 2 diabetes: Nutrient pathophysiology and the transition from health to disease

Associate Professor of Medicine and Medical Director of Clinical Research Texas Diabetes Institute, University of Texas Health Science Center, San Antonio, TX, USA
Professor Emeritus of Medicine, Department of Medicine, Faculdade de Medicina da Universidade de Ribeirão Preto, SP, Brazil / Founder & Honorary President of the International Medical Association of Nutrology
Type 2 Diabetes Nutrient Patho-physiology Genetics and Obesity

Abstract

From a Nutrology point of view, type 2 diabetes is a multi-factorial form of clinical “malnutrition” resulting from the intake of an imbalanced diet in combination with adverse environmental conditions and in the presence of predisposing genetic factors. In this review article, we present evidence of a close association between clinical obesity in a specific genetic background as the pillars of the process underlying the development of type 2 diabetes. We review the basics of the energy balance and the role of fat storage and body distribution in the pathogenesis of insulin resistance. We describe some molecular aspects of nutrients under normal physiology and during the metabolic and hormonal abnormalities that accompany type 2 diabetes. We conclude with a brief discussion of the principles behind popular dietary recommendations aimed at preventing the full development of diabetes mellitus and its complications.

Metrics

Metrics Loading ...

References

  1. WHO. Diabetes Action Now. 2004
  2. King H, Aubert RE, Herman WH. Global Burden of Diabetes 1995 -2025: prevalence, numerical estimates and projections. Diabetes Care 1998; 21:1414-31.
  3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes, estimates for the year 2000 and projections 2030. Diabetes Care 2004: 27:1047-1053
  4. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286 1195-2000.
  5. Rickheim P. et al. 2004; Type 2 Diabetes BASICS Curriculum Guide. 2004. International Diabetes Center, IDC Publishing, 2nd edition.
  6. Bray G.A. Obesity illustrated. In: An Atlas of Obesity and Weight Control. New York, NY: Parthenon Publishing; 2003, pp. 49.
  7. Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal glucose metabolism in humans. Am J Physiol: Endocrinol and Metab 1999; 276(39):E78-E84
  8. DeFronzo RA. et al. Lilly Lecture. The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37:667-687.
  9. Shulman G. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106(2):171-76.
  10. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32(Suppl. 3):14-23.
  11. Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R, DeFronzo RA, Cusi K. Dose response effect of elevated plasma FFA on insulin signaling. Diabetes 2005; 54; 1640-48
  12. Cersosimo E, DeFronzo, RA. Insulin Resistance and Endothelial Dysfunction: The Road Map for Cardiovascular Diseases. Diabetes Metab Res Rev 2006; 22:423-36.
  13. Reyna S, Ghosh S, Tantiwong P, Cersosimo E et al. Elevated Toll-Like Receptor-4 Expression and Signaling in Muscle From Insulin-Resistant Subjects. Diabetes 2008; 57:2595-2602.
  14. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn RC, Mandarino L. Insulin resistant differentially affects PI-3 kinase and MAP-kinase-mediated signaling in human muscle. J Clin Invest 2000; 105:311-20.
  15. Bantle JP, Wylie-Rosett J, Albright Al, Apovian CM, Clark NG, Franz MJ, et al. American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31:S61-S78.
  16. Mayo Clinic Staff. The Mayo Clinic Diet: a weight loss program for life, published by Mayo Foundation, 2008.
  17. Larsen RN, Mann NJ, Maclean E, Shaw JE. The effect of high-protein diet, low carbohydrate diets in the treatment of type 2 diabetes: a 12 month randomized controlled trial. Diabetologia 2011; 54:731-740.
  18. Larsen TM, Dalskow S-M, van Baak M, et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med 2010; 363:2102-13.
  19. Shai I, Schwarzfuchs D, Henkin Y et al. Weight loss with a low carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 359(3): 229-41.
  20. Jenkins DJA, Srichaikul K, Kendall CWC, Sievepiper JL, Abdulnour S, Mirrahimi A, Meneses C, Nishi S, He X, Lee S, So YT, Esfahani A, Mitchel S, Parker TL, Vidgen E, Josse RG, Leiter LA. The relation of low glycemic index fruit consumption to glycemic control and risk factors for coronary heart disease in type 2 diabetes. Diabetologia 2011; 54:271-79.
  21. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(2):393-403.
  22. St-Onge MP, Keller KL, Heymsfield SB. Changes in childhood food consumption patterns: a cause for concern I light of increasing body weights. Am J Clin Nutr 2003; 78:1068-73.
  23. Brownell KD, Kelly D, Farley T, Willett C, Popkin P, Barry M. Chaloupka F, Frank J, Thompson T, Joseph W. Ludwig L, David S. The public health and economic benefits of taxing sugar-sweetened beverages. N Engl J Med 2009; 361:1599-2005.
  24. Esposito K, Maiorino MI, Ciotola M, et al. Effects of a Mediterranean-style diet on the need for anti-hyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med 2009; 151:306-14.
  25. Lemaitre RN, King IB, Mozzaffarian D, Kuller LH, Tracey RP, Siscovick DS. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease and nonfatal myocardial infarction in older adults; The CardioVascular Health Study. Am J Clin Nutr 2003; 77:319-25.
  26. Sacks F, et al. Effects on blood pressure of reduced dietar sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. New Engl J Med 2001, 344(1): 3–10.
  27. Lewington S., Clarke R, Qizilbash, N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-13.
  28. Karanja N, Erlinger TP, Pao-Hwa L, Miller ER, 3rd, Bray GA. The DASH Diet for High Blood Pressure: From Clinical Trial to Dinner Table. Cleveland Clinic Journal of Medicine 2004 September; 71(9):745-53.
  29. Sachs FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different composition of fat, protein, and carbohydrates. N Engl J Med 2009; 360:859-873.
  30. Salmeron J, Ascherio A, Rimm EB, et al. Dietary fiber, glycemic load and risk of NIDDM in men. Diabetes Care 1997; 20:545-550.
  31. Schenk S., Horowitz J.F. Acute exercise increases triglyceride synthesis in skeletal muscle and prevents fatty-acid induced insulin resistance. J Clin Invest 2007; 117(6):1690-98.
  32. Toledo FGS, Menshikova EV, Ritov VB, Azuma K, Radikova Z, DeLany J, Kelley D. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. Diabetes 2007; 56:2142-47
  33. DeFronzo RA, Buse JB, Kendall DM et al. Safety and efficacy of exenatide in the treatment of type 2 diabetes patients. Diabetes Care 2005; 28:1092-1100
  34. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372(9645): 1240–50.
  35. Roth JD, et al. Insulin Signaling Pathways. Proc Natl Acad Sci USA. 2008.
  36. Greco A.V. et al. Insulin Resistance in Morbid Obesity: Reversal with Intra-Myocellular Fat Depletion. Diabetes 2002; 51: 144-51.
  37. Mandeep B, Swangjit S, Paul P, Lou JH, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA. Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients. The J Clin Endocrinol & Metab 2004; 89(1): 200-06
  38. Klein, S, Fontana L, Young LV, Coggan AR, Kilo C, Patterson, BW, Mohammed BS. Absence of an Effect of Liposuction on Insulin Action and Risk Factors for Coronary Heart Disease. New Engl J Med 2004; 350:2549-57.

How to Cite

Cersosimo, E., & Oliveira, J. E. D. de. (2022). Nutrology and type 2 diabetes: Nutrient pathophysiology and the transition from health to disease. International Journal of Nutrology, 5(1), 6–13. https://doi.org/10.1055/s-0040-1701422